IL-6 Blockade with Clazakizumab is Associated with Low Myeloid Cell Activation and Increased Type 2 Immune Responses in Non-survivors of COVID-19. (academic.oup.com)

Authors: Stoddart L … Karaba AH Journal: Journal of Infectious Diseases Published: 2026-10-27 DOI: https://doi.org/10.1093/infdis/jiag510